Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.
Freenome (FRNM) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
Freenome (NASDAQ:FRNM) Stock Has Average Target Price of $18.00 According to Analysts
Shares of Freenome (NASDAQ: FRNM - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research ana…
Freenome NASDAQ: FRNM reported third-quarter revenue of $183.5 million, driven largely by revenue recognition following the U.S. Food and Drug Administration's approval of its blood-based colorectal cancer screening test…
● GlobeNewsWireOct 20, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and …
● GlobeNewsWireOct 15, 2026 · 16:29 ETCOMPANY'S OWN WORDS
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to release its financial…
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
- Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention - - Overall detection of colorectal cancer remaine…
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target the vast unscreened colorectal market. FRNM's SimpleScreen CRC, now out-licensed to Abbott, offers a patient-friendly, bl…
Article counts from the last market-wide feed page, across every symbol we track and not just FRNM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.